QIDP for Motif's iclaprim triggers L22M placing

FDA granted Qualified Infectious Disease Product (QIDP) designation to iclaprim from Motif Bio plc (LSE:MTFB) to treat hospital-acquired bacterial pneumonia

Read the full 209 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE